Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen‐Hua Liu, Jia‐Horng Kao, Jow-Jyh Huang et al.|Gut|2021Cited by 39
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen‐Hua Liu, Jia‐Horng Kao, Pin‐Nan Cheng et al.|Journal of Hepatology|2024Cited by 33
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in TaiwanChen‐Hua Liu, Jia‐Horng Kao, Po-Yueh Chen et al.|Hepatology International|2021Cited by 32
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen‐Hua Liu, Jia‐Horng Kao, Chi-Yi Chen et al.|Clinical and Molecular Hepatology|2021Cited by 22
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen‐Hua Liu, Jia‐Horng Kao, Cheng‐Yuan Peng et al.|Hepatology International|2023Cited by 21